NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Neuroendocrine Prostate Cancer

Interventions

DRUG: [68Ga]Ga-PSMA-11
DRUG: [68Ga]GA-DOTA-TATE
DRUG: [68Ga]Ga-NeoB
DRUG: [177Lu]Lu-PSMA-617
DRUG: [177Lu]Lu-DOTA-TATE
DRUG: [177Lu]Lu-NeoB
DRUG: L-Lysine HCl-L-Arginine HCl, 2.5 %,
DRUG: Gonadotropin-releasing hormone (GnRH) analogues
DRUG: GnRH antagonists
DRUG: Antiemetics & antinauseants
DRUG: Metoclopramide

Sponsor

Novartis Pharmaceuticals